Jing Ma
Beijing, Beijing Municipality, 100034, China
Location status: Recruiting
NCT Number: NCT05813392
To explore the efficacy of dCBT-I therapy for chronic insomnia among breast cancer survivors in China, we propose to conduct a randomized, parallel controlled clinical study in breast cancer survivors using a smartphone Chinese application (app) "resleep". Breast cancer survivors with chronic insomnia were recruited from our Breast Disease Center and externally, with the waiting group as a parallel control and the dCBT-I treatment group as an intervention group, in a 1:1 sample size. Intervention group (dCBT-I treatment group) will receive full self-help dCBT-I administered by smartphone APP for 6 weeks. The control group (waiting for treatment group) will not receive any additional interventions based on the original conventional treatment and will be followed up as planned, waiting for treatment.At the end of the 3-month follow-up, the decision to receive treatment was made according to the patient's wishes. The primary endpoint was the insomnia severity index (ISI) at the end of treatment and at 3 months of treatment.
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
Beijing, Beijing Municipality, 100034, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
Time frame: immediately post-treatment
Time frame: 3-months follow-up
Time frame: 6-months follow-up
Time frame: up to 6-months follow-up
Online sleep diary measures(total sleep time, sleep efficiency, sleep latency, numbers and duration of awakenings during sleep)
Time frame: up to 6-months follow-up
The GAD-7 is a simple and reliable anxiety screening tool. There are a total of seven questions with a score of 0-3 for each question. The total score provides a possible score from 0-21. A score of 10 or greater indicates further evaluation is required.
Time frame: up to 6-months follow-up
The PHQ-9 is a simple and validated self-assessment scale for depressive disorders, with good reliability and validity both as an aid to the diagnosis of depression and in the assessment of symptom severity. It has a total of nine items with a total score of 0-27.
Time frame: up to 6-months follow-up
The SF-12 is a simplified version of the quality of life questionnaire generated based on the SF-36 scale, consisting of 12 items, containing eight dimensions, and assessing an individual's perceived physical and mental health status. The scale is scored on a percentage scale, and after obtaining a crude score, it is converted using the standardized scoring method. It includes the SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Higher scores indicate higher levels of quality of survival.
7)The smart bracelet data (recording parameters such as bedtime, sleep duration, number of awakenings during sleep, wake-up time, and sleep quality)
Time frame: up to 6-months follow-up
Time frame: up to 6-months follow-up
Time frame: up to 6-months follow-up
EORTC: The European Organization for Research and Treatment of Cancer; QOL-C30: Quality of Life Questionnaire Core 30.
Peking University First Hospital
Other
Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) for Chronic Insomnia in Breast Cancer Survivors, A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07429578
Anxiety Disorders, Chronic Insomnia
São Paulo, Brazil
View Trial DetailsNCT07542756
Chronic Insomnia, Chronic Insomnia Disorder
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07216261
Chronic Insomnia, Dyssomnias
Durham, North Carolina, United States
View Trial DetailsNCT07156383
Chronic Insomnia, Dyssomnias
Notre Dame, Indiana, United States
View Trial Details